LFCR
Price
$6.44
Change
+$0.02 (+0.31%)
Updated
Oct 15 closing price
Capitalization
247.34M
21 days until earnings call
Intraday BUY SELL Signals
PAHC
Price
$37.98
Change
+$0.05 (+0.13%)
Updated
Oct 15 closing price
Capitalization
1.45B
26 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LFCR vs PAHC

LFCR vs PAHC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
LFCR vs. PAHC commentary
Oct 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LFCR is a Hold and PAHC is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LFCR with price predictions
Oct 15, 2026

LFCR in downward trend: price expected to drop as it breaks its higher Bollinger Band on September 28, 2026

LFCR broke above its upper Bollinger Band on September 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In 37 of the 40 cases the stock fell afterwards. This puts the odds of success at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LFCR as a result. In 75 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for LFCR turned negative on October 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 40 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LFCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for LFCR entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

LFCR moved above its 50-day moving average on September 28, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for LFCR crossed bullishly above the 50-day moving average on September 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Following a +56.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where LFCR advanced for three days, in 207 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LFCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (192.308) is normal, around the industry mean (43.873). P/E Ratio (51.231) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (2.661) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.222) is also within normal values, averaging (178.797).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LFCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

A.I.Advisor
a Summary for PAHC with price predictions
Oct 15, 2026

PAHC in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 02, 2026

PAHC broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In 32 of the 40 cases the stock fell afterwards. This puts the odds of success at 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 62 cases where PAHC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PAHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

The Aroon Indicator for PAHC entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 29, 2026. You may want to consider a long position or call options on PAHC as a result. In 64 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

The Moving Average Convergence Divergence (MACD) for PAHC just turned positive on October 01, 2026. Looking at past instances where PAHC's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.

PAHC moved above its 50-day moving average on September 30, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PAHC crossed bullishly above the 50-day moving average on October 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.

Following a +3.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAHC advanced for three days, in 212 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.761) is normal, around the industry mean (43.873). P/E Ratio (14.700) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.350) is also within normal values, averaging (2.152). Dividend Yield (0.013) settles around the average of (0.005) among similar stocks. P/S Ratio (0.953) is also within normal values, averaging (178.797).

The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. PAHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

FUNDAMENTALS RATINGS
LFCR vs PAHC: Fundamental Ratings
LFCR
PAHC
OUTLOOK RATING
1..100
6992
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
10
Undervalued
PROFIT vs RISK RATING
1..100
10062
SMR RATING
1..100
10034
PRICE GROWTH RATING
1..100
3654
P/E GROWTH RATING
1..100
594
SEASONALITY SCORE
1..100
750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PAHC's Valuation (10) in the Pharmaceuticals Major industry is significantly better than the same rating for LFCR (90) in the Industrial Specialties industry. This means that PAHC’s stock grew significantly faster than LFCR’s over the last 12 months.

PAHC's Profit vs Risk Rating (62) in the Pharmaceuticals Major industry is somewhat better than the same rating for LFCR (100) in the Industrial Specialties industry. This means that PAHC’s stock grew somewhat faster than LFCR’s over the last 12 months.

PAHC's SMR Rating (34) in the Pharmaceuticals Major industry is significantly better than the same rating for LFCR (100) in the Industrial Specialties industry. This means that PAHC’s stock grew significantly faster than LFCR’s over the last 12 months.

LFCR's Price Growth Rating (36) in the Industrial Specialties industry is in the same range as PAHC (54) in the Pharmaceuticals Major industry. This means that LFCR’s stock grew similarly to PAHC’s over the last 12 months.

LFCR's P/E Growth Rating (5) in the Industrial Specialties industry is significantly better than the same rating for PAHC (94) in the Pharmaceuticals Major industry. This means that LFCR’s stock grew significantly faster than PAHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LFCRPAHC
RSI
ODDS (%)
Bearish Trend 1 day ago
87%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
74%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
71%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 18 days ago
77%
Bullish Trend 1 day ago
74%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 4 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
67%
COMPARISON
Comparison
Oct 16, 2026
Stock price -- (LFCR: $6.44 vs. PAHC: $37.98)
Brand notoriety: LFCR and PAHC are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: LFCR: 53% vs. PAHC: 73%
Market capitalization -- LFCR: $247.34M vs. PAHC: $1.45B
LFCR [@Pharmaceuticals: Generic] is valued at $247.34M. PAHC’s [@Pharmaceuticals: Generic] market capitalization is $1.45B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LFCR’s FA Score shows that 1 FA rating(s) are green while PAHC’s FA Score has 1 green FA rating(s).

  • LFCR’s FA Score: 1 green, 4 red.
  • PAHC’s FA Score: 1 green, 4 red.
According to our system of comparison, PAHC is a better buy in the long-term than LFCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LFCR’s TA Score shows that 4 TA indicator(s) are bullish while PAHC’s TA Score has 5 bullish TA indicator(s).

  • LFCR’s TA Score: 4 bullish, 6 bearish.
  • PAHC’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PAHC is a better buy in the short-term than LFCR.

Price Growth

LFCR (@Pharmaceuticals: Generic) experienced а +0.16% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was +1.55% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.28%. For the same industry, the average monthly price growth was -2.33%, and the average quarterly price growth was +12.08%.

Reported Earning Dates

LFCR is expected to report earnings on Nov 06, 2026.

PAHC is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-4.28% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
LFCR
Daily Signal:
Gain/Loss:
PAHC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AN159.806.61
+4.31%
AutoNation
REPL11.750.36
+3.16%
Replimune Group
MSI456.394.66
+1.03%
Motorola Solutions
NTRP1.67-0.04
-2.34%
NextTrip
NNNN3.30-0.27
-7.56%
Anbio Biotechnology

LFCR and

Correlation & Price change

A.I.dvisor tells us that LFCR and SHPH have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LFCR and SHPH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LFCR
1D Price
Change %
LFCR100%
+0.31%
SHPH - LFCR
31%
Poorly correlated
+6.91%
COLL - LFCR
28%
Poorly correlated
+2.98%
PAHC - LFCR
27%
Poorly correlated
+0.13%
TLRY - LFCR
27%
Poorly correlated
+2.23%
VTRS - LFCR
25%
Poorly correlated
+4.47%
More

PAHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with ZTS. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then ZTS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PAHC
1D Price
Change %
PAHC100%
+0.13%
ZTS - PAHC
61%
Loosely correlated
+4.16%
ELAN - PAHC
47%
Loosely correlated
+4.39%
VTRS - PAHC
29%
Poorly correlated
+4.47%
LFCR - PAHC
27%
Poorly correlated
+0.31%
AKBA - PAHC
27%
Poorly correlated
-0.93%
More